Sotera Health (SHC) Earnings Date & Reports

Key Takeaways

• Third-quarter 2026 revenue rose 4.4% year over year to $324.9 million, topping consensus estimates of roughly $319.7 million.
• Adjusted earnings per share (EPS) of $0.29 beat the $0.27 consensus and climbed 12% versus the prior-year period.
• Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) increased 3.9% to $170.7 million, with margins expanding sequentially to 52.5%.
• Sterigenics grew 8.2% in constant currency, while Nordion declined 11.5% on expected Cobalt-60 harvest timing.
• Management reaffirmed its full-year 2026 outlook but flagged softening medical device demand, particularly in Europe.
• For more on SHC's Major News, Today's Price Move, Price Targets, and Forecast, be sure to explore these dedicated pages.
• Discover Trending AI Robots to see how AI-driven trading tools are identifying market opportunities right now.

Earnings Context and Why It Matters

Sotera Health occupies a mission-critical position in the healthcare supply chain, providing sterilization, lab testing, and advisory services through its Sterigenics, Nordion, and Nelson Labs businesses. Its results serve as a real-time barometer of medical device and pharmaceutical production volumes. The third quarter follows a strong second quarter in which the company raised its full-year outlook, raising the bar for the latest report. Investors were closely watching whether momentum at Sterigenics and Nelson Labs could continue and whether any cracks in end-market demand would emerge. The latest results delivered another beat, but management's softer tone on the fourth quarter — citing weakening medical device demand, mostly in Europe — shifted the focus from the headline numbers to the sustainability of growth.

Reported Results

Sotera Health reported third-quarter 2026 net revenues of $324.9 million, up 4.4% on both an as-reported and constant currency basis compared to the prior-year period. Net income on a GAAP (Generally Accepted Accounting Principles) basis was $58 million, or $0.20 per diluted share. Adjusted EPS rose 12% year over year to $0.29, ahead of the $0.27 consensus, while adjusted EBITDA increased 3.9% to $170.7 million, slightly above the roughly $167.8 million analysts expected. Adjusted EBITDA margin expanded nearly 100 basis points sequentially to 52.5%.

At the segment level, Sterigenics delivered revenue of $209 million, up 8.5% as reported and 8.2% in constant currency, supported by 4.8% pricing and improved volume and mix. Nelson Labs grew revenue 8.8% to $61 million, or 9.2% in constant currency, helped by an increase in expert advisory services activity. Nordion revenue declined 12.4% to $55 million, reflecting the anticipated timing of Cobalt-60 harvest schedules, though its segment income margin still improved 71 basis points to 61.3%.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market using technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs with customizable filters covering industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to surface trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking earnings-driven movers like SHC, it offers a structured way to identify actionable setups across the healthcare services sector and beyond.

Market Reaction and Investor Sentiment

Sotera Health's clean top-and-bottom-line beat initially drew a positive response, but the mood quickly became more guarded. The company had raised its constant-currency outlook in the second quarter, so investors entered this report expecting continued upward revisions. Instead, management only reaffirmed guidance and described softening medical device demand that began mid-to-late in the third quarter as "broad-based," framing the fourth quarter with a more cautious tone. This shift — combined with a trimmed reported revenue range reflecting a smaller foreign-exchange benefit — tempered enthusiasm. The result was a beat that carried a caveat: the strongest segment growth of the year arrived alongside the first notable demand caution of the year, leaving sentiment mixed as the market digested the forward commentary.

Forward Outlook and Key Factors to Monitor

Looking ahead, the central question is whether the medical device softness management described is a temporary pause or the start of a broader slowdown. Sotera Health guided Sterigenics to roughly 6% constant-currency revenue growth in the fourth quarter, below the 8.2% posted in the third, and noted it does not expect the normal seasonal step-up. Investors should watch for any change in commentary from major medical device customers and whether the European softness spreads to other regions.

Nelson Labs is expected to moderate from its strong third quarter, while Nordion's performance will continue to hinge on the timing of Cobalt-60 harvests. On the financial side, net leverage improved to 2.9x, within the company's long-term target, and a Moody's credit rating upgrade in early October strengthened the balance sheet narrative. With capital expenditures projected at $200 million to $225 million for 2026 and a meaningful step-down anticipated in 2027, free cash flow conversion will be another key metric to track. Management reiterated its full-year 2026 adjusted EPS guidance of $0.95 to $1.01.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations